Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation. (June 2013)

• Record Type: Journal Article
• Authors: Sánchez-Ortega, Isabel; Patiño, Beatriz; Muñoz, Carmen; Arnan, Montserrat; Peralta, Teresa; Clopés, Ana; Fernández de Sevilla, Alberto; Duarte, Rafael F.
• Is Part Of: Journal of medical economics. Volume 16:Number 6(2013)
• Page Start: 736
• Page End: 743
• Publication Date: 2013-06
• Subjects: Medical care -- Cost control -- Periodicals; Medical economics -- Periodicals; 362.10941
• DOI: 10.3111/13696998.2013.791301
• Languages: English
• ISSNs: 1369-6998

Abstract

<abstract> <title>Abstract</title> <sec id="ss1"> <title>Purpose:</title> <p>To evaluate the cost-effectiveness of posaconazole vs itraconazole in the prevention of invasive fungal infections (IFIs) in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT).</p> </sec> <sec id="ss2"> <title>Methods:</title> <p>Total hospital-based costs from initial admission for allo-HSCT until day 100 after transplantation were evaluated for 49 patients in whom the clinical efficacy of antifungal prophylaxis with posaconazole vs itraconazole had been previously analyzed and reported. Clinical and economic data were used to determine the incremental costs per IFI avoided and per life-year gained for posaconazole compared with itraconazole. Confidence intervals for the incremental cost-effectiveness ratio (ICER) and a cost-effectiveness acceptability curve were estimated through bootstrapping with the bias-corrected percentile method.</p> </sec> <sec id="ss3"> <title>Results:</title> <p>According to our analysis, the total cost of allo-HSCT per patient during the 100-day fixed-treatment period was €46, 562 in the posaconazole group (<italic>n</italic> = 33) and €45, 080 in the itraconazole group (<italic>n</italic> = 16). However, the reduction in the incidence of IFI and the improved outcome with posaconazole resulted in a favorable ICER of €11, 856 per IFI avoided and €5218 per life-year gained. With the outcomes of the bootstrap procedure, the cost-effectiveness acceptability curve was constructed. Assuming a threshold of €30, 000 per life-year gained, the ICER based on life-years gained is acceptable with 75% certainty.</p> </sec> <sec id="ss4"> <title>Limitations:</title> <p>This evaluation is based on data from a single-center, non-randomized study. Preference weights or utilities were not available to calculate quality-adjusted life-years. Extra-mural costs were only partially evaluated from a hospital perspective. Indirect costs and economic consequences are not included.</p> </sec> <sec id="ss5"> <title>Conclusions:</title> <p>This economic evaluation compared direct medical costs associated with posaconazole or itraconazole treatment; the data suggest that posaconazole may be cost-effective as antifungal prophylaxis during the early high-risk neutropenic period and up to 100 days after allo-HSCT.</p> </sec> </abstract>